Ocrelizumab vs Upadacitinib

## Ocrelizumab vs Upadacitinib: Overview

This comparison examines the pharmacological differences between **Ocrelizumab** and **Upadacitinib**.

## Mechanism of Action

**Upadacitinib**: Selective JAK1 inhibitor reducing signaling from cytokines implicated in autoimmune diseases.

## Pharmacokinetics

**Half-life**: Ocrelizumab — N/A; Upadacitinib — 9-14 hours.

## Chemical Properties

**Molecular Formula**: Ocrelizumab — N/A; Upadacitinib — C17H19F3N6O.

**Molecular Weight**: Ocrelizumab — N/A; Upadacitinib — 380.3700 g/mol.

**Type**: Ocrelizumab — Antibody; Upadacitinib — Small molecule.